In conclusion, our current data demonstrate an advance in mortalin targeting in MTC cells and, consistent with our previous observations, support the potential of mortalin as a target for the design of a molecular therapy for MTC. Here, HSPA9 is linked to medullary thyroid gland carcinoma.